Keywords: idera, pharma, extends, tlr, program, massachusetts, usa-based
Idera Pharma extends TLR program
Article | 22 May 2006
Massachusetts, USA-based Idera Pharmaceuticals says that it is expanding its portfolio of drug candidates which target Toll-like receptors (TLR) to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
